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Purpose: Transforming growth factor-β (TGF-β) is considered to be essential to induce epithelial-to-mesenchymal
transition (EMT) which plays central roles in wound healing in ocular fibrotic complication. The present study investigates
whether small interference RNAs (siRNAs) targeting the type II receptor of TGF-β (TβRII) could be used to minimize
the TGF-β action.
Methods: TGF-β receptor type II (TβRII) specific siRNAs designed from the Nakamura human gene sequence were used
to transfect the cultured lens epithelial cells (LECs). The optimal transfection of scramble siRNA-Cy3 labeled duplexes
in cultured LECs were examined by laser scanning confocal microscope and flow cytometry. TβRII protein expression
and transcript levels were analyzed by immunofluorescence, western blotting, and real time PCR, respectively. Western
blotting was performed to examine protein expression of fibronectin and alpha-smooth muscle actin (α-SMA). Scratch
assay was used to determine cell migration. Cell morphology was observed after transfection by inverted microscope.
Results: The optimal transfection rate of scramble siRNA-Cy3 labeled duplexes was efficient in that nearly to 50% in
cultured LECs. TβRII specific siRNAs significantly reduced the receptor transcript and protein expression in cultured
LECs. The gene knockdown inhibited LECs transdifferentiation, as it abrogated the expression of fibronectin and α-SMA,
and retarded cell migration on the scratch assay. In addition, after transfection with TβRII specific siRNA, the cultured
LECs did not show fibroblast-like shape which was one of the feature signs of EMT. Wound scratch assays indicated that
the number of cultured LECs migrated into the wounded area was significantly lower in TβRII specific siRNA treated
group (12.8±3.27/7.85 mm2), compared with normal (57.8±3.06/7.85 mm2) and scrambled RNA transfected group
(50.8±3.64/7.85 mm2; p<0.0001).
Conclusions: Our results provided additional evidence to support that TGF-β pathway was involved in the development
of EMT of human posterior capsule opacification, while how TβRII was involved should be further investigated.
As  an  important  refractive  media,  the  ocular  lens  is
transparent and provides part of the refractive power needed
to focus images on the retina. Recently, there has been great
interest  in  human  posterior  capsule  opacification  (PCO)
which are secondary cataracts due to residual lens epithelial
cells (LECs) transdifferentiation after cataract surgery [1]. To
investigate  the  mechanisms  involved  in  transformation  of
LECs may help to prevent and treat this type of cataract.
Epithelial-mesenchymal transition (EMT) is a process in
which epithelial cells lose their differentiated phenotypes and
change its morphology and transcriptional program to the
characteristic of a mesenchymal cell [2]. The results of both
cell study and human sample pathological study supported
that  EMT  was  an  important  LECs  transformation  during
wound healing after cataract surgery [3-5].
Transforming growth factor-β (TGF-β) is member of a
large metazoan family of multifunctional cytokines involving
in a wide range of cellular processes, including cell growth,
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differentiation, inflammation, and wound healing [6-8]. TGF-
β orchestrates the EMT of various epithelia tissues in response
to injury [9-11]. Although five members of the TGF-β family
have been identified, only TGF-β isoforms 1, 2, and 3 have
been detected in mammals with TGF-β2 predominant [12,
13].
TGF-β2  was  a  strong  inducer  of  transformation  and
pathologic  fibrosis  of  epithelial  cells  by  modulating
components of the extracelluar matrix (ECM) [14,15]. This
process involves the activation of several EMT-associated
target genes and accumulation of fibroblastic/myofibroblastic
makers:  α-smooth  muscle  actin  (α-SMA)  and  fibronectin
[16-19]. TGF-β signaling is initiated by TGF-β binding to type
II receptor of TGF-β (TβRII), followed by its recruitment and
phosphorylation of type I receptor of TGF-β (TβRI) [6].
Regulating the biologic activities of residual LECs during
the  wound  healing  process  may  be  a  potential  anti-EMT
strategy for cataract surgery, and blocking TGF-β signaling
seems promising [20,21]. The use of anti-TGF-β antibody and
antisense  oligonucleotides  to  block  the  TGF-β  action  for
glaucoma surgery has been reported [22-24].
RNA  interference  (RNAi)  can  easily  and  effectively
inhibit the expression of a specific gene by which double
stranded RNA triggers the destruction of mRNAs sharing the
Molecular Vision 2012; 18:1238-1246 <http://www.molvis.org/molvis/v18/a129>
Received 24 March 2012 | Accepted 8 May 2012 | Published 11 May 2012
© 2012 Molecular Vision
1238same sequence [25]. Therefore, RNAi can prevent synthesis
of a protein encoded by the target mRNA [26]. Recently,
RNAi-mediated gene silencing has been shown to be efficient
in  mammalian  cells,  and  this  has  led  to  the  increasing
feasibility  of  RNAi  technology  for  the  therapy  of  certain
human diseases [27].
Therefore, this study aimed to investigate whether the
RNAi strategy targeting TβRII could effectively manipulate
the  activation  and  proliferation  of  LECs  during  the  EMT
process after cataract surgery.
METHODS
Cell culture: SRA01/04 cells (a human lens epithelial cell line
from  Shang  Fu  professor,  ATCC,  Manassas,  VA)  were
cultured  in  Dulbecco's  Modified  Eagle  Medium  (DMEM;
GIBCO, Grand Island, NY) supplemented with 10% fetal
bovine serum (FBS; HyClone, Logan, UT), 2.2 g/l sodium
bicarbonate, and 10 mmol/l HEPES 2-[4-(2-Hydroxyethyl)-1-
piperazinyl]ethanesulfonic acid) buffer in a humidified 37 °C
incubator with 5% CO2 atmosphere.
TβRII  siRNA  sequences  design:  Three  pairs  of  siRNAs
targeting  TβRII  were  designed  according  to  the  TβRII
sequence  in  GenBank  (NM_003242).  All  the  duplex
sequences and target sequences of these siRNAs identified
were BLASTed against the GenBank database. Three siRNA
sequences that cover different regions of the TβRII coding
sequence without homology to the non-TβRII sequence were
custom  synthesized  by  Ribobio  (Guangzhou,  China).  The
target sequences (5′ to 3′) and the siRNA duplexes for these
three ones, designed as hT1, hT2, and hT3, are shown in Table
1. In addition, a nonspecific, scrambled siRNA duplex with
Cy3  labeled,  served  as  a  control  to  determine  optimal
conditions for siRNA transfection, were also synthesized by
Ribobio.
Transfection  of  scramble  siRNA-Cy3  labeled  duplexes  to
optimize transfection conditions: Cells were plated in 24-well
culture plate at 1×104 cells/well to 30% confluence overnight.
For transfection, the culture medium was removed from the
cells and was replaced with 500 µl Opti-MEM® I medium
(GIBCO,  invitrogen,  Guangzhou,  China)  for  each  well.
Lyophilized  siRNAs  were  dissolved  in  Rnase-free  H2O
(pH=7.4) and stored at −20 °C before use. Lipofectamine™
2000  reagent  (Invitrogen)  were  kept  for  5  min  at  room
temperature before mixing with Cy3-conjugated scrambled
siRNA. The cultured LECs were transfected with scrambled
(control) siRNA (20, 40, 50, 60 or 80 nM final concentration)
using  Lipofectamine™  2000  reagent,  following  the
manufacturer's protocol. The cells were transfected for 6 h for
analyses.  Also  as  controls,  cells  were  either  untreated  or
treated with Lipofectamine™ 2000 reagent.
Transfection of Target siRNA duplexes: The cultured LECs
were transfected with TβRII specific siRNA duplex (80 nM
final concentration) or scrambled siRNA (80 nM) as above.
The cells were harvested 24, 48, or 72 h after transfection for
analyses.  Also  as  controls,  cells  were  either  untreated  or
treated only with Lipofectamine™ 2000 reagent.
Analysis  of  transfection  optimization:  Transfected  with
scrambled  siRNA  (20,  40,  50,  60  or  80  nM  final
concentration) after 6 h, cells were rinsing three times with
PBS and replaced with complete culture medium. Images
were  photographed  with  Zeiss  LSM  510  confocal  laser
scanning device (Zeiss, Oberkochen, Germany). The group of
cells transfected with scrambled siRNA (60, 80 or 100 nM)
were  trypsinized,  harvested  and  resuspended  in  PBS  at  a
density of 1×106 cells/ml for flow cytometry (BD Bioscience,
San Jose, CA) analysis with a 550-nm laser. Treatments were
performed in triplicate and the results are displayed as the
average transfected percentage of total cell number.
Detection of TβRII mRNA expression by real time PCR: Total
RNA  was  extracted  using  Trizol  ®  Reagent  (Invitrogen,
Carlsbad, CA) and reverse transcribed for 45 min at 45 °C
using  TaKaRa  RNA  PCR  Kit  (AMV)  Ver.3.0  (TaKaRa,
Dalian, China). Real-time PCR reactions was performed in an
ABI  7500  real  time  PCR  system  (Applied  Biosystems,
Invitrogen,  Guangzhou,  China)  using  the  following  PCR
parameters: 93 °C for 3 min followed by 30 cycles at 93 °C
for 30 s, 55 °C for 30 s, and 72 °C for 45 s. Results were
evaluated on the basis of mRNA copy number/1 μg of total
RNA and normalized by β-actin (ACTB) as an internal control.
Each sample was tested at least three times. The sequences of
the primers were as follows: TβRII, 5′-ACC ACC AGG GCA
TCC AGA T-3′(sense), 5′-TGA AGC GTT CTG CCA CAC
A-3′ (antisense); ACTB, 5′-GCA TGG GTC AGA AGG ATT
CCT-3′ (sense), 5′-TCG TCC CAG TTG GTG ACG AT-3′
(antisense).
TABLE 1. TARGET AND DUPLEX SEQUENCES FOR TΒRII SPECIFIC SIRNAS.
siRNA
duplex
TβRII sequence (5′-3′) siRNA duplex sequences
hT1 TCCTGCATGAGCAACTGCA (5′-3′) 5′ UCCUGCAUGAGCAACUGCA dTdT 3′
    (3′-5′) 3′ dTdT AGGACGUACUCGUUGACGU 5′
hT2 GCATGAGAACATACTCCAG (5′-3′) 5′ GCAUGAGAACAUACUCCAG dTdT 3′
    (3′-5′) 3′ dTdT CGUACUCUUGUAUGAGGUC 5′
hT3 GGCCAAGCTGAAGCAGAAC (5′-3′) 5′ GGCCAAGCUGAAGCAGAAC dTdT 3′
    (3′-5′) 3′ dTdT CCGGUUCGACUUCGUCUUG 5′
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1239Immunofluorescence staining: After transfection, cells were
fixed in 4% paraformaldehyde solution, permeabilized with
0.1%  Triton  X-100,  and  stained  with  rabbit  anti-TβRII
antibody  (1:50,  TGF-β  RII  (C-16):sc220;  Santa  Cruz
Biotechnology Inc., Santa Cruz, CA) and FITC conjugated
goat  anti-rabbit  IgG  (1:32;  Southern  Biotechnology,
Birmingham, AL) . The nuclei of the cells were counterstained
with  Hoechst  33342  (5  µg/ml;  Sigma,  Guangzhou  weiga
science  and  technology  company,  Guangdong,  China).
Images were captured with a Zeiss LSM 510 confocal laser
scanning device.
Western  blotting:  After  siRNA  transfection,  HLECs  were
lysed in an ice-cold Triton lysis buffer (50 mM, pH 7.5;
Invitrogen).  Equal  amount  of  protein  (20  μg/lane)  was
resolved  on  a  12%  sodium  dodecyl  sulfate  (SDS)-
polyacrylamide gel. The proteins were then transferred to
polyvinylidene  fluoride  membranes  (PVDF  membranes;
Millipore,  Guangzhou  weiga  science  and  technology
company)  for  probing  with  rabbit  anti-TβRII  antibody
(1:1,000) and horseradish peroxidase (HRP) conjugated goat
anti-rabbit IgG (1:5,000; Santa Cruz Biotechnology).
In  addition,  cells  (48  h  after  transfection)  after
normalizing against the protein content in cell lysates, equal
amount of protein (20 µg/lane) was resolved in 12%SDS–
PAGE.  The  proteins  were  then  transferred  to  PVDF
membranes for probing with rabbit anti-human fibronectin
monoclonal antibody (1:1,000; Epitomics, Guangzhou weiga
science and technology company), rabbit anti-human alpha-
smooth muscle actin (α-SMA) polyclonal antibody (1:300,
No:  ab5694;  Abcam,  Guangzhou  weiga  science  and
technology  company)  and  HRP  (1:5,000),  respectively.
GAPDH  (glceraldehyde  3-phosphate  dehydrogenase)
staining served as an internal control.
Signals  were  detected  by  chemiluminescence  and
analyzed  by  densitometry  using  Image  J  software  (image
processing and analysis in Java).
Cell migration assay: Cultured LECs after transfection were
scratched with a sterile P20 pipette tip. After cultures were at
approximately 90% confluence, a standard 200-μl yellow tip
was drawn across the center of each well to produce the
wound. The migration of cells into the wound was examined
by inverted microscope at another 48 h after transfection. At
least 10 microscopic fields were analyzed and the average cell
number that migrated into the wound area was calculated.
Cell morphology: SRA01/04 cells at 48 h after transfection
were observed. The morphology of each group was examined
by inverted microscope.
Statistical analysis: Statistical analysis was performed with a
statistical software package (SPSS for Windows, version 16.0,
SPSS, Chicago, IL). The data of each group were compared
and are expressed as the mean±SD, with p<0.05 taken to
indicate  significance.  Statistical  comparions  between  the
groups were performed using analysis of variance (AVOVA)
with the Bonferonni-Dunn adjustment.
Figure 1. Qualitative analysis of optimal transfection of different concentration of Cy3-labeled scrambled siRNA for SRA01/04 cells.
Distribution of Cy3-labeled scrambled siRNA (red fluorescence) in SRA01/04 cells at 6 h after scrambled siRNA transfection with a final
concentration gradient of 20 (A), 40 (B), 50 (C), 60 (D), or 80 nM (E). Cells incubated with Lipofectamine™ 2000 reagent alone (no siRNA)
served as blank control which did not show fluorescence appearance (F). Bar: 25 μm.
Molecular Vision 2012; 18:1238-1246 <http://www.molvis.org/molvis/v18/a129> © 2012 Molecular Vision
1240RESULTS
Optimize  conditions  for  scramble  siRNA-Cy3  labeled
duplexes transfection: The optimal ratio of scrambled siRNA
transfection  was  analyzed  by  laser  scanning  confocal
microscopy  with  Cy3  staining  (Figure  1).  Red  punctuate
staining of scrambled siRNA on the surface of transfected
cells were increased gradually in number or intensity (Figure
1A-E).  Transfection  efficiency  was  also  evaluated  by
measuring the percentage of cells containing Cy3-conjugated
siRNA using flow cytometry analysis (Figure 2). The optimal
transfection rate was efficient in that nearly to 50% with 80
nM final concentration (Figure 2C). Both methods revealed
that  the  effect  of  cells  displayed  red  fluorescence  of  the
luciferase siRNA was in a dose dependent manner. The effect
of varied concentration of scrambled siRNAs were tested.
Scrambled siRNA with 100 nM induced elongation, apoptosis
and decreased viability of cells (data not shown).
Suppression  of  TβRII  protein  and  mRNA  expression:
Immunofluorescence showed punctuate staining of TβRII on
the surface of untreated control HLECs (Figure 3B). The
staining was also observed in the cytoplasm, particularly in
the perinuclear area. When treated with 80 nM hT3 for 48 h,
the TβRII staining intensity was markedly reduced (Figure
3H). At 80 nM, hT1 and hT2 did not markedly suppress the
TβRII staining intensity. The inhibitory effect was observed
in  varied  degrees  for  all  three  siRNAs  with  other
concentrations (60 and 100 nM) and time points (24 and 72
h).  This  response  however  was  not  evident  at  the  lowest
concentration (60 nM) and the shortest time point (24 h)
tested.  Overall,  hT3  showed  the  greatest  inhibition  effect
among  the  three  sequences.  Cells  treated  with  scrambled
siRNA (Figure 3E) exhibited a similar staining intensity and
pattern as the untreated control cells (Figure 3B).
Western blotting (Figure 4A) yielded a 72 kDa band
immunoreactive to anti-TβRII in the vehicle treated control
and scrambled siRNA transfected samples. At 48 h, 80 nM
hT3 siRNA induced marked decreased signal intensity for
TβRII  compared  with  vehicle  or  scrambled  RNA  treated
controls.  Densitometric  analysis  indicated  80%–85%
reduction of TβRII protein expression in hT3 siRNA treated
samples. The hT1 and hT2 group exhibited a similar staining
intensity and pattern as the untreated control cells.
TβRII transcript levels were examined by real time PCR
using ACTB to normalize the data. Finger 4B showed the mean
normalized TβRII gene expression as determined on the basis
of mRNA copy number/1μg of total RNA. Compared with
scrambled siRNA, hT3 at 80 nM significantly reduced the
level of TβRII transcripts at the 48 h time points (p<0.0001).
TβRII siRNA downregulates myofibroblast markers of α-SMA
and  fibronectin  protein  expression:  Western  blotting  was
performed  to  determine  whether  siRNAs  inhibit  the
fibronectin  and  α-SMA  protein  expression  which  was  a
reflection  of  decreased  myofibroblast  markers  secretion.
Figure  2.  Quantitative  analysis  of
optimal  transfection  of  different
concentration of Cy3-labeled scrambled
siRNA for SRA01/04 cells. The Cy3-
labeled scrambled siRNA transfection
rates of SRA01/04 cells after incubating
for  6  h  were  evaluated  by  flow
cytometry. A: Blank group: 0%. B: 60
nM  Cy3-labeled  scrambled  siRNA:
0.8%. C: 80 nM Cy3-labeled scrambled
siRNA: 49.6%. D: 100 nM Cy3-labeled
scrambled siRNA: 8.8%.
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1241HLECs were transfected for 48 h. Proteins in the media were
subjected to electrophoresis. A 220 kDa fibronectin and a
34 kDa α-SMA (Figure 5) were observed in all samples.
Treatment with 80 nM hT3 resulted in decreased fibronectin
and α-SMA protein expression (Figure 5). The siRNA elicited
a great effect with 80 nM hT3 (89% and 57% reduction of
fibronectin and α-SMA protein expression than the scrambled
siRNA treated sample).
TβRII siRNA inhibits the migration of HLECs in the wound-
healing assay: Wound scratch assays indicated that HLECs
migrated into the wounded area (Figure 6 A-C). Within 48 h,
average of cell numbers that migrated to the wound area for
untreated  control  and  scrambled  RNA  transfected  groups
were 57.8±3.06/7.85 mm2 and 50.8±3.64/7.85 mm2 (Figure
6D),  respectively.  By  contrast,  80  nM  hT3
(12.8±3.27/7.85  mm2;  Figure  6D)  transfected  cells  was
significantly decreased (p<0.0001).
TβRII  siRNA  influence  cell  morphology:  Cells  after  48  h
transfection was observed by inverted microscopy. Untreated
control  and  scrambled  RNA  transfected  cells  were
proliferated  adhesively  (Figure  7A,B).  By  contrast,  the
proliferation of cells that transfected with 80 nM hT3 cells
(Figure 7C) was significantly suppressed. Transfected HLECs
showed apoptotic changes such as condense of nucleus and
lessened volume relative to untreated control and scrambled
RNA transfected cells. The latter exhibited a fibroblast-like
morphology obviously.
Figure 3. Transfection with targeting siRNAs suppressed TβRII protein expression by immunofluorescence staining. Untreated SRA01/04
cells (A-C), SRA01/04 cells treated with 80 nM scrambled siRNA for 48 h (D-F), or treated with 80 nM hT3 (G-I) were observed under
immunofluorescence microscope. Staining of nuclei with Hoechst 33342 (blue) is shown in A, D, and G. TβRII expression is shown in B,
E, and H. Compared with the control cells (B and E), TβRII staining of cells treated with hT3 siRNA was weaker (H). The morphology after
the siRNA treatment were somewhat altered. Note the exclusively cytoplasmatic localization of TβRII expression (C, F, and I). Bar: 25 μm.
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1242DISCUSSION
The present results showed that the change of fibroblast-like
morphology and the migration of human lens epithelial cells
were remarkably prohibited after transfection with specific
siRNA  of  TβRII,  as  well  as  the  downregulation  of
myofibroblast  markers  of  α-SMA  and  fibronectin  protein
expression. Currently, the criteria for defining an EMT in vitro
have varied in different studies, but it is generally accepted
that it involves the acquisition of a mesenchymal morphology
and mesenchymal markers. Therefore, the present siRNA of
TβRII may be regarded to possibly lead to a prohibition of
EMT in the PCO.
Cataract surgery can induce a wound-healing response in
the lens that leads to PCO which is believed to arise from the
proliferation, migration, and EMT of residual lens cells. TGF-
β2 has recently proved to be a ubiquitous factor associated
with  wound-healing  response  and  influence  LEC
proliferation, migration, and EMT [16,28]. TGF-β2 initiates
cellular and molecular changes in lens cells that are relevant
with PCO development, including myofibroblast formation,
wrinkling  of  the  lens  capsule,  identification  of  fibroblast
markers, and deposition of ECM [29-31]. However, to our
knowledge,  there  were  no  previous  reports  about  the
Figure  4.  Effect  of  targeting  siRNAs
suppressed TβRII protein and mRNA
expression  by  western  blot  and  RT–
PCR. A: siRNAs suppress TβRII protein
expression in SRA01/04 cells. Total cell
lysates  from  SRA01/04  cells  treated
with  hT1,  hT2,  and  hT3  siRNA  or
control, scrambled siRNA for 48 h were
separated on 12% SDS polyacrylamide
gels and immunoblotted with a TβRII
specific antibody. Lane 5 contains lysate
from  cells  incubated  with
Lipofectamine™  2000  reagent  alone
(no siRNA). Lane 4 contains lysate from
cells  treated  with  80  nM  scrambled
siRNA. Lanes 1, 2, and 3 contain lysates
of cells treated with hT1,hT2, and hT3
siRNA at a final concentration of 80 nM.
The TβRII band is indicated. B: siRNA
reduces levels of TβRII transcript. RNA
was  prepared  from  cells  treated  with
scrambled siRNA or hT 3 siRNA for 48
h at 80 nM/ concentration. Following
conversion to cDNA, the samples were
analyzed  by  real  time  PCR  using
primers to TβRII. The bar graphs show
the  mean  expression  levels  of  TβRII
transcript normalized to ACTB relative
to  that  of  scrambled  siRNA  treated
controls. Asterisks indicate that the data
are  significantly  different  from  the
scrambled  controls  (p<0.0001,  n=3,
one-way ANOVA, Dunnett-test).
Figure 5. TβRII siRNA interferes with
fibronectin  and  alpha-smooth  muscle
actin (α-SMA) production. The level of
fibronectin  secreted  and  α-SMA
expression  to  the  culture  media  was
analyzed by western blotting. Samples
were from cultures untreated (lane 3),
treated with scrambled siRNA (lane 2),
or 80 nM (lane 1) hT3. The fibronectin
(Fn) and α-SMA bands are labeled.
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1243relationship between the receptor of TGF-β and the change of
lens cells in the research of development of EMT of PCO.
Our results were consistent with previous reports. In the
Liu et al. [29] study, TGF-β induced lens epithelial cells in
explants to undergo an extensive and rapid elongation with
features that distinguished it from fibroblast growth factor
(FGF)-induced fiber differentiation, and TGF-β also induced
accumulation of extracellular matrix, capsule wrinkling, cell
death by apoptosis, and distinctive arrangements of cells. In
the Hales et al. [5] study, TGF-β induced rapid cell elongation
and formation of characteristic spindle-shaped cells which
contained  alpha-smooth  muscle  actin,  a  marker  for
myofibroblastic cells and a protein not normally found in the
lens. Similarly, numerous in vitro and in vivo studies indicate
that this TGF-β-induced EMT is part of a wound healing
response  in  lens  epithelial  cells  and  is  characterized  by
induced expression of numerous extracellular matrix proteins
(laminin,  collagens  I,  III,  tenascin,  fibronectin,
proteoglycans),  intermediate  filaments  (desmin,  alpha-
smooth muscle actin) and various integrins (alpha2, alpha5,
alpha7) [32].
Ocular  fibrotic  wound  response  is  a  major  cause  of
impaired vision and blindness, and excessive post-operative
scarring  often  leads  to  failure  of  cataract  surgery.  Some
previous  studies  have  tried  to  use  antimitotics  or
antimetabolites  to  control  postoperative  PCO  [33,34],
however, severe blinding complications including hypotony,
maculopathy and intraocular infection were observed even
Figure  6.  TβRII  siRNA  blocks
SRA01/04  cells  migration.  Inverted
microscope  images  demonstrating
migration of HLECs (A), cells treated
for 48 h with scrambled siRNA (B), or
cells treated for 48 h with 80 nM hT3
(C). Black straight lines mark the wound
edges. D: Bar graph showing mean cell
numbers  migrating  to  wound  area  in
each  specimen  (n=10);  error  bars
represent the standard error of the mean.
Asterisks  denote  values  significantly
different  from  those  of  scrambled
siRNA  treated  controls  (p<0.0001).
Experiments  were  repeated  3  times,
yielding  similar  results.  The  bar
represents 25 μm.
Figure 7. TβRII siRNA inhibits the morphological fibroblast-like change of SRA01/04 cells. Inverted microscope images observing cell
morphology of HLECs (A), cells treated for 48 h with scrambled siRNA (B), or cells treated for 48 h with 80 nM hT3 (C). Untreated control
and scrambled RNA transfected cells were proliferated adhesively (A and B). By contrast, the proliferation of cells that transfected with 80
nM hT3 cells (C) was significantly suppressed. Transfected HLECs showed apoptotic changes such as condense of nucleus and lessened
volume relative to untreated control and scrambled RNA transfected cells. The latter exhibited a fibroblast-like morphology obviously. The
bar represents 25 μm.
Molecular Vision 2012; 18:1238-1246 <http://www.molvis.org/molvis/v18/a129> © 2012 Molecular Vision
1244after  antimitotics  use  extraocularly  in  the  clinic  [35-37].
Additionally, several experimental attempts have been made
to find an appropriate therapeutic target to prevent PCO, such
as proteasome inhibitors MG-132, lactacystin [38] or gene
transfer [39,40], but none has proven effective either because
of its toxic effect on other ocular tissues or because of only
partial or differential effect on the major causes of PCO, such
as  LEC  proliferation,  migration,  and  transdifferentiation.
However,  in  the  recent  ten  years,  RNA  interference  has
become an essential method for in vitro knockdown of target
gene  and  has  been  used  experimentally  to  prevent  ocular
neovascularization  and  inflammation  [41-43].  Antisense
oligonucleotides or ribozymes for TGF-β were shown to be
effective in wound healing by animal and cell studies [24,44,
45]. Therefore, as a potential therapeutic way for control of
EMT for PCO, RNA interference of TGF-β or TβRII to block
the pathway deserved a further investigation.
There were pros and cons in this study. The present study
took advantages in the novelty of research of the relationship
between inhibition of the receptor for TGF-β, i.e., the TβRII,
and the change of lens epithelial cells, and was also prior by
using of high efficient RNAi. However, due to the absence of
animal study and due to the complexity of EMT, our study
failed to give a comprehensive explanation of how TβRII was
involved in the development of EMT in PCO. Further studies
are required.
In  summary,  the  current  study  demonstrates  that
downregulation of the TβRII mRNA by application of siRNA
inhibit the expression of myofibroblast markers (fibronectin
and α-SMA), the morphological fibroblast-like change and
the  migration  of  human  lens  epithelial  cells.  Our  results
provided additional evidence to support that TGF-β pathway
was involved in the development of EMT of human posterior
capsule opacification, while how TβRII was involved should
be investigated in the further study.
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